Cytori pioneered the therapeutic use of a mixed or heterogenous population of uncultured (i.e. fresh) cell types found in adipose tissue. Cytori developed the Celution® System to deliver a clinical grade population of such cells rapidly and reliably at the point-of-care. Cytori’s global patent portfolio is built around the Celution System and the numerous therapeutic uses for which the Celution System output can be tailored. The Company’s intellectual property for market protection includes the following:
- Technological leadership and global portfolio of issued and pending patents related to adipose-derived stem and regenerative cells
- Proprietary know-how for tissue processing and delivery of adipose-derived stem and regenerative cells
- First mover advantage in establishing brand loyalty
- Partnerships with leading healthcare brands including GE Healthcare, Olympus Corporation, and Green Hospital
- Substantial capital investment in the development and manufacturing of the technology by Cytori and Olympus Corporation
- Exclusive supply for some critical components
Cytori believes that a comprehensive strategy to protect the Celution® System and Cytori’s approach to cell therapy from competitive forces is in place.>> Learn More: Intellectual Property Fact Sheet